296 related articles for article (PubMed ID: 15203987)
1. Loading DCs with Ag.
Vari F; Hart DN
Cytotherapy; 2004; 6(2):111-21. PubMed ID: 15203987
[TBL] [Abstract][Full Text] [Related]
2. DCs as targets for vaccine design.
Belz G; Smith C; Bharadwaj M; Rice A; Jackson D
Cytotherapy; 2004; 6(2):88-98. PubMed ID: 15203984
[TBL] [Abstract][Full Text] [Related]
3. The immune response to breast cancer, and the case for DC immunotherapy.
Allan CP; Turtle CJ; Mainwaring PN; Pyke C; Hart DN
Cytotherapy; 2004; 6(2):154-63. PubMed ID: 15203992
[TBL] [Abstract][Full Text] [Related]
4. DC in multiple myeloma immunotherapy.
Turtle CJ; Brown RD; Joshua DE; Hart DN
Cytotherapy; 2004; 6(2):128-37. PubMed ID: 15203989
[TBL] [Abstract][Full Text] [Related]
5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells and their role in cancer immunotherapy.
Jalili A
Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
[TBL] [Abstract][Full Text] [Related]
7. RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy.
Hsu AK; Kerr BM; Jones KL; Lock RB; Hart DN; Rice AM
Biol Blood Marrow Transplant; 2006 Aug; 12(8):855-67. PubMed ID: 16864056
[TBL] [Abstract][Full Text] [Related]
8. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.
Du YC; Lin P; Zhang J; Lu YR; Ning QZ; Wang Q
Tissue Antigens; 2006 May; 67(5):368-76. PubMed ID: 16671943
[TBL] [Abstract][Full Text] [Related]
9. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH
J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells from bench to bedside and back.
Adema GJ
Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
[TBL] [Abstract][Full Text] [Related]
12. Genetically engineered dendritic cell-based cancer vaccines (review).
Bubeník J
Int J Oncol; 2001 Mar; 18(3):475-8. PubMed ID: 11179474
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
[TBL] [Abstract][Full Text] [Related]
14. Presentation of tumour antigens by dendritic cells and challenges faced.
Robson NC; Hoves S; Maraskovsky E; Schnurr M
Curr Opin Immunol; 2010 Feb; 22(1):137-44. PubMed ID: 20116984
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells in cancer immunotherapy.
Schuler G
Eur J Immunol; 2010 Aug; 40(8):2123-30. PubMed ID: 20853498
[TBL] [Abstract][Full Text] [Related]
16. DCs in lymphoma--biology and therapeutic aspects.
Schultze JL; Fiore F; von Bergwelt-Baildon M
Cytotherapy; 2004; 6(2):138-47. PubMed ID: 15203990
[No Abstract] [Full Text] [Related]
17. Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy.
Wu Y; Wang L; Zhang Y
Cell Mol Immunol; 2004 Oct; 1(5):351-6. PubMed ID: 16285894
[TBL] [Abstract][Full Text] [Related]
18. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
Shurin MR; Gregory M; Morris JC; Malyguine AM
Expert Opin Biol Ther; 2010 Nov; 10(11):1539-53. PubMed ID: 20955111
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
20. Reengineering dendritic cell-based anti-cancer vaccines.
Koski GK; Cohen PA; Roses RE; Xu S; Czerniecki BJ
Immunol Rev; 2008 Apr; 222():256-76. PubMed ID: 18364007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
